Skip to main content
Top

Open Access 23-10-2024 | Liraglutide | Original Research

The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery

Authors: Yuanyuan Shen, Yuanhao Huang, Yuqin Ouyang, Xinyue Xiang, Xuehui Chu, Bingqing Zhang, Tao Han, Wenjuan Tang, Wenhuan Feng

Published in: Diabetes Therapy

Login to get access

Abstract

Introduction

The safety and efficacy of liraglutide as a weight loss intervention in individuals who remain obese within 1 year post-metabolic surgery remain unclear. This study aimed to evaluate the effects and safety of liraglutide (1.8 mg) in patients with persistent obesity at 6 months postoperatively.

Methods

This retrospective cohort study included 61 patients who remained obese (body mass index [BMI] ≥ 28.0 kg/m2) at 6 months postoperatively. Among these patients, 27 were treated with 1.8 mg of liraglutide for 12 weeks, whereas 34 served as controls. The primary endpoint was the change in total weight loss (%TWL) after 24 weeks. Changes in weight, BMI, complications, and adverse events were also assessed.

Results

The liraglutide group showed a greater reduction in %TWL than the control group (11.6% ± 1.1% vs. 4.9% ± 1.0%), with an estimated treatment difference of 6.6% (95% confidence interval [CI], 3.7–9.6%, P < 0.01). The adjusted mean differences in the reduction of weight and BMI between the liraglutide and control groups were − 6.2 kg (95% CI − 8.9 to − 3.4, P < 0.01) and − 3.0 kg/m2 (95% CI − 4.2 to − 1.7, P < 0.01), respectively. The liraglutide group exhibited increased rates of remission in non-alcoholic fatty liver disease and hypertension. No serious adverse reactions were observed.

Conclusions

For patients who remained obese at 6 months postoperatively, 12-week liraglutide treatment resulted in increased weight loss, improved metabolic control, and high rate of remission for obesity-related metabolic diseases after 24 weeks. Earlier and more timely adjuvant weight loss medication intervention based on BMI within 1 year postoperatively may enhance weight loss after metabolic surgery.
Graphical abstract available for this article.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34.CrossRefPubMed Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34.CrossRefPubMed
2.
go back to reference Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021;9(6):373–92.CrossRefPubMed Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021;9(6):373–92.CrossRefPubMed
3.
go back to reference Brissman M, Beamish AJ, Olbers T, Marcus C. Prevalence of insufficient weight loss 5 years after Roux-en-Y gastric bypass: metabolic consequences and prediction estimates: a prospective registry study. BMJ Open. 2021;11(3):e046407.CrossRefPubMedPubMedCentral Brissman M, Beamish AJ, Olbers T, Marcus C. Prevalence of insufficient weight loss 5 years after Roux-en-Y gastric bypass: metabolic consequences and prediction estimates: a prospective registry study. BMJ Open. 2021;11(3):e046407.CrossRefPubMedPubMedCentral
4.
go back to reference Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55.CrossRefPubMedPubMedCentral Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55.CrossRefPubMedPubMedCentral
5.
go back to reference Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA Surg. 2018;153(5):427–34.CrossRefPubMed Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA Surg. 2018;153(5):427–34.CrossRefPubMed
6.
go back to reference Shen Y, Zhang B, Hu X, Zhang N, Huang Y, Han T, et al. Metabolic surgery results in greater metabolic benefits in patients who achieve healthy weight. Surg Obes Relat Dis. 2024. Shen Y, Zhang B, Hu X, Zhang N, Huang Y, Han T, et al. Metabolic surgery results in greater metabolic benefits in patients who achieve healthy weight. Surg Obes Relat Dis. 2024.
7.
go back to reference El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg. 2021;31(4):1755–66.CrossRefPubMedPubMedCentral El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg. 2021;31(4):1755–66.CrossRefPubMedPubMedCentral
8.
go back to reference Melton GB, Steele KE, Schweitzer MA, Lidor AO, Magnuson TH. Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes. J Gastrointest Surg. 2008;12(2):250–5.CrossRefPubMed Melton GB, Steele KE, Schweitzer MA, Lidor AO, Magnuson TH. Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes. J Gastrointest Surg. 2008;12(2):250–5.CrossRefPubMed
9.
go back to reference Cohen RV, Petry TB. How to address weight regain after bariatric surgery in an individualized way. Rev Endocr Metab Disord. 2023;24(5):993–1002.CrossRefPubMed Cohen RV, Petry TB. How to address weight regain after bariatric surgery in an individualized way. Rev Endocr Metab Disord. 2023;24(5):993–1002.CrossRefPubMed
10.
go back to reference Istfan NW, Lipartia M, Anderson WA, Hess DT, Apovian CM. Approach to the patient: management of the post-bariatric surgery patient with weight regain. J Clin Endocrinol Metab. 2021;106(1):251–63.CrossRefPubMed Istfan NW, Lipartia M, Anderson WA, Hess DT, Apovian CM. Approach to the patient: management of the post-bariatric surgery patient with weight regain. J Clin Endocrinol Metab. 2021;106(1):251–63.CrossRefPubMed
11.
go back to reference Yimcharoen P, Heneghan HM, Singh M, Brethauer S, Schauer P, Rogula T, et al. Endoscopic findings and outcomes of revisional procedures for patients with weight recidivism after gastric bypass. Surg Endosc. 2011;25(10):3345–52.CrossRefPubMed Yimcharoen P, Heneghan HM, Singh M, Brethauer S, Schauer P, Rogula T, et al. Endoscopic findings and outcomes of revisional procedures for patients with weight recidivism after gastric bypass. Surg Endosc. 2011;25(10):3345–52.CrossRefPubMed
12.
go back to reference Saliba C, El Rayes J, Diab S, Nicolas G, Wakim R. Weight regain after sleeve gastrectomy: a look at the benefits of re-sleeve. Cureus. 2018;10(10):e3450.PubMedPubMedCentral Saliba C, El Rayes J, Diab S, Nicolas G, Wakim R. Weight regain after sleeve gastrectomy: a look at the benefits of re-sleeve. Cureus. 2018;10(10):e3450.PubMedPubMedCentral
13.
go back to reference Hansen D, Decroix L, Devos Y, Nocca D, Cornelissen V, Dillemans B, et al. Towards optimized care after bariatric surgery by physical activity and exercise intervention: a review. Obes Surg. 2020;30(3):1118–25.CrossRefPubMed Hansen D, Decroix L, Devos Y, Nocca D, Cornelissen V, Dillemans B, et al. Towards optimized care after bariatric surgery by physical activity and exercise intervention: a review. Obes Surg. 2020;30(3):1118–25.CrossRefPubMed
14.
go back to reference Schwartz J, Chaudhry UI, Suzo A, Durkin N, Wehr AM, Foreman KS, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8.CrossRefPubMed Schwartz J, Chaudhry UI, Suzo A, Durkin N, Wehr AM, Foreman KS, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8.CrossRefPubMed
15.
go back to reference Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280–9.CrossRefPubMed Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280–9.CrossRefPubMed
16.
go back to reference Torrego-Ellacuria M, Barabash A, Larrad-Sainz A, Hernandez-Nunez GM, Matia-Martin P, Perez-Ferre N, et al. Weight regain outcomes after bariatric surgery in the long-term follow-up: role of preoperative factors. Obes Surg. 2021;31(9):3947–55.CrossRefPubMed Torrego-Ellacuria M, Barabash A, Larrad-Sainz A, Hernandez-Nunez GM, Matia-Martin P, Perez-Ferre N, et al. Weight regain outcomes after bariatric surgery in the long-term follow-up: role of preoperative factors. Obes Surg. 2021;31(9):3947–55.CrossRefPubMed
17.
go back to reference Alvarez V, Carrasco F, Cuevas A, Valenzuela B, Munoz G, Ghiardo D, et al. Mechanisms of long-term weight regain in patients undergoing sleeve gastrectomy. Nutrition. 2016;32(3):303–8.CrossRefPubMed Alvarez V, Carrasco F, Cuevas A, Valenzuela B, Munoz G, Ghiardo D, et al. Mechanisms of long-term weight regain in patients undergoing sleeve gastrectomy. Nutrition. 2016;32(3):303–8.CrossRefPubMed
18.
go back to reference Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310(22):2416–25.PubMedPubMedCentral Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310(22):2416–25.PubMedPubMedCentral
19.
go back to reference van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784–93.CrossRefPubMed van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784–93.CrossRefPubMed
20.
go back to reference Mok J, Adeleke MO, Brown A, Magee CG, Firman C, Makahamadze C, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg. 2023;158(10):1003–11.CrossRefPubMedPubMedCentral Mok J, Adeleke MO, Brown A, Magee CG, Firman C, Makahamadze C, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg. 2023;158(10):1003–11.CrossRefPubMedPubMedCentral
21.
go back to reference Vinciguerra F, Piazza L, Di Stefano C, Degano C, Pulvirenti A, Baratta R, et al. High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery. Front Nutr. 2023;10:1183899.CrossRefPubMedPubMedCentral Vinciguerra F, Piazza L, Di Stefano C, Degano C, Pulvirenti A, Baratta R, et al. High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery. Front Nutr. 2023;10:1183899.CrossRefPubMedPubMedCentral
22.
go back to reference Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451–62.CrossRefPubMed Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451–62.CrossRefPubMed
23.
go back to reference Society CD. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes. 2021;41(5):482–548. Society CD. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes. 2021;41(5):482–548.
24.
go back to reference Brethauer SA, Kim J, el Chaar M, Papasavas P, Eisenberg D, Rogers A, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11(3):489–506.CrossRefPubMed Brethauer SA, Kim J, el Chaar M, Papasavas P, Eisenberg D, Rogers A, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11(3):489–506.CrossRefPubMed
25.
go back to reference Brethauer SA, Kim J, El Chaar M, Papasavas P, Eisenberg D, Rogers A, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg. 2015;25(4):587–606.CrossRefPubMed Brethauer SA, Kim J, El Chaar M, Papasavas P, Eisenberg D, Rogers A, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg. 2015;25(4):587–606.CrossRefPubMed
26.
go back to reference Qu Y, Song YY, Chen CW, Fu QC, Shi JP, Xu Y, et al. Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2021;12(4):e00323.CrossRefPubMedPubMedCentral Qu Y, Song YY, Chen CW, Fu QC, Shi JP, Xu Y, et al. Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2021;12(4):e00323.CrossRefPubMedPubMedCentral
27.
go back to reference Wu J, Qiu L, Cheng XQ, Xu T, Wu W, Zeng XJ, et al. Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. Sci Rep. 2017;7(1):5456.CrossRefPubMedPubMedCentral Wu J, Qiu L, Cheng XQ, Xu T, Wu W, Zeng XJ, et al. Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. Sci Rep. 2017;7(1):5456.CrossRefPubMedPubMedCentral
28.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
29.
go back to reference Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 30 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):12323.CrossRef Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 30 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):12323.CrossRef
30.
go back to reference Jensen AB, Renström F, Aczél S, Folie P, Biraima-Steinemann M, Beuschlein F, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017–25.CrossRefPubMedPubMedCentral Jensen AB, Renström F, Aczél S, Folie P, Biraima-Steinemann M, Beuschlein F, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017–25.CrossRefPubMedPubMedCentral
31.
go back to reference Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500.CrossRefPubMed Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500.CrossRefPubMed
32.
go back to reference Clapp B, Wynn M, Martyn C, Foster C, O’Dell M, Tyroch A. Long term (7 or more years) outcomes of the sleeve gastrectomy: a meta-analysis. Surg Obes Relat Dis. 2018;14(6):741–7.CrossRefPubMed Clapp B, Wynn M, Martyn C, Foster C, O’Dell M, Tyroch A. Long term (7 or more years) outcomes of the sleeve gastrectomy: a meta-analysis. Surg Obes Relat Dis. 2018;14(6):741–7.CrossRefPubMed
33.
go back to reference Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10(2):81–9.CrossRefPubMed Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10(2):81–9.CrossRefPubMed
34.
go back to reference Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–50.CrossRefPubMedPubMedCentral Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–50.CrossRefPubMedPubMedCentral
Metadata
Title
The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery
Authors
Yuanyuan Shen
Yuanhao Huang
Yuqin Ouyang
Xinyue Xiang
Xuehui Chu
Bingqing Zhang
Tao Han
Wenjuan Tang
Wenhuan Feng
Publication date
23-10-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01643-1

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more